Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00726648 | CDP323 Biomarker Study | PHASE1 | COMPLETED | 71 | — | — | Jul 1, 2008 | Mar 1, 2009 | Sep 12, 2011 | 2 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CDP323 | DRUG | 50mg capsules, 100mg bid for 4 weeks |
| Placebo | DRUG | placebo capsules for 4 weeks |
Inclusion Criteria: * Female and male subjects aged 18-65 years * Relapsing form of MS with at least one clinical relapse in the 24 months before screening; * Screening EDSS score of 0-6.5; * Must be fully immunocompetent * Female subjects of childbearing potential must agree to practice contracept...